Skip to content
Back to NTLA

Intellia Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
20
Purchases
1
Sales
19
Purchase value
$1.40M
Sale value
$2.27M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

John M LeonardDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Nov 3, 2026Period of report Nov 2, 20260001193125-26-445417
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 2, 2026
Common StockF1F29,000$11.99$107.91K1,138,064Direct
Filing footnotes · 3
  1. F1The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.65 to $12.60, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
  3. F3Shares held by the John M. Leonard 2015 Irrevocable Trust.
Open on SEC EDGAR
Michael P DubeVP, Chief Accounting Officer
4
Filed Oct 6, 2026Period of report Oct 2, 20260001193125-26-415541
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 2, 2026
Common StockF11,864$12.43$23.17K65,022Direct
Filing footnotes · 1
  1. F1Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2026, and does not represent a volitional trade by the Reporting Person.
Open on SEC EDGAR
John M LeonardDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Aug 24, 2026Period of report Aug 20, 20260001193125-26-363567
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 21, 2026
Common StockF12,785$13.00$36.21K1,147,064Direct
SaleAug 20, 2026
Common StockF1F219,890$12.60$250.61K1,149,849Direct
Filing footnotes · 3
  1. F1The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price.
  3. F3Shares held by the John M. Leonard 2015 Irrevocable Trust.
Open on SEC EDGAR
Edward J Dulac IIIEVP, Chief Financial Officer
4
Filed Jul 24, 2026Period of report Jul 22, 20260001193125-26-316279
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 22, 2026
Common StockF1F28,111$11.25$91.25K148,175Direct
Filing footnotes · 2
  1. F1Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2026, and does not represent a volitional trade by the Reporting Person.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.25 to $11.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 22, 2026 at each separate price.
Open on SEC EDGAR
Edward J Dulac IIIEVP, Chief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Jul 6, 2026Period of report Jul 2, 20260001821530-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 2, 2026
Common StockF14,677$18.00$84.19K156,286Direct
Filing footnotes · 1
  1. F1The reported sale of 4,677 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 8, 2025.
Open on SEC EDGAR
Michael P DubeVP, Chief Accounting Officer
4
Filed Jul 6, 2026Period of report Jul 1, 20260002019493-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 1, 2026
Common StockF1F22,641$16.78$44.32K66,886Direct
Filing footnotes · 2
  1. F1Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 1, 2026, and does not represent a volitional trade by the Reporting Person.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.78 to $17.12, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2026 at each separate price.
Open on SEC EDGAR
James BastaEVP, General Counsel
4
Filed Mar 3, 2026Period of report Mar 1, 20260001193125-26-088260
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF21,211$13.78$16.69K156,794Direct
Filing footnotes · 3
  1. F1Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit
  2. F2Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2026, and does not represent a volitional trade by the Reporting Person.
  3. F3This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.
Open on SEC EDGAR
Eliana ClarkEVP, Chief Technical Officer
4
Filed Mar 3, 2026Period of report Mar 1, 20260001193125-26-088241
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 2, 2026
Common StockF2607$13.78$8.36K93,864Direct
Filing footnotes · 3
  1. F1Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
  2. F2Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2026, and does not represent a volitional trade by the Reporting Person.
  3. F3This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.
Open on SEC EDGAR
John M LeonardDirector · President and CEO
4
Filed Jan 7, 2026Period of report Jan 5, 20260001193125-26-006294
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Common StockF134,146$9.21$314.48K1,013,339Direct
Filing footnotes · 2
  1. F1Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.
  2. F2Shares held by the John M. Leonard 2015 Irrevocable Trust.
Open on SEC EDGAR
Birgit C SchultesEVP, Chief Scientific Officer
4
Filed Jan 7, 2026Period of report Jan 5, 20260001193125-26-006292
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Common StockF1F28,508$9.21$78.36K98,533Direct
Filing footnotes · 2
  1. F1Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.
  2. F2Includes 925 and 932 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.
Open on SEC EDGAR
James BastaEVP, General Counsel
4
Filed Jan 7, 2026Period of report Jan 5, 20260001193125-26-006291
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Common StockF110,397$9.21$95.76K101,528Direct
Filing footnotes · 1
  1. F1Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.
Open on SEC EDGAR
Fred E CohenDirector
4
Filed Jan 7, 2026Period of report Jan 5, 20260001193125-26-006288
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseJan 5, 2026
Common StockF1F2150,000$9.35$1.40M207,453Direct
Filing footnotes · 2
  1. F1Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies.
  2. F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.13 to $9.68, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on January 5, 2026 at each separate price.
Open on SEC EDGAR
David LebwohlEVP, Chief Medical Officer
4
Filed Jan 7, 2026Period of report Jan 5, 20260001193125-26-006283
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Common StockF1F211,903$9.21$109.63K121,249Direct
Filing footnotes · 2
  1. F1Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.
  2. F2Includes 1,022 and 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.
Open on SEC EDGAR
Eliana ClarkEVP, Chief Technical Officer
4
Filed Jan 7, 2026Period of report Jan 5, 20260001193125-26-006278
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Common StockF1F29,515$9.21$87.63K87,118Direct
Filing footnotes · 2
  1. F1Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.
  2. F2Includes 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2025.
Open on SEC EDGAR
Edward J Dulac IIIEVP, Chief Financial Officer
4
Filed Jan 7, 2026Period of report Jan 5, 20260001193125-26-006275
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Common StockF16,379$9.21$58.75K99,683Direct
Filing footnotes · 1
  1. F1Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.
Open on SEC EDGAR
Michael P DubeVP, Chief Accounting Officer
4
Filed Jan 7, 2026Period of report Jan 5, 20260001193125-26-006264
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Common StockF12,989$9.21$27.53K52,277Direct
Filing footnotes · 1
  1. F1Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.
Open on SEC EDGAR
John M LeonardDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Dec 12, 2025Period of report Dec 11, 20250001193125-25-317551
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 11, 2025
Common StockF1F249,959$9.49$474.11K1,077,115Direct
SaleDec 11, 2025
Common StockF1F332,832$9.47$310.92K1,044,283Direct
SaleDec 11, 2025
Common StockF1F45,355$9.59$51.35K1,038,928Direct
Filing footnotes · 6
  1. F1The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.64, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.57 to $9.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
  5. F5Shares held by the John M. Leonard 2015 Irrevocable Trust.
  6. F6The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.